CSL Past Earnings Performance

Past criteria checks 2/6

CSL has been growing earnings at an average annual rate of 7%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 8.3% per year. CSL's return on equity is 11.9%, and it has net margins of 18.1%.

Key information

7.0%

Earnings growth rate

6.2%

EPS growth rate

Biotechs Industry Growth12.9%
Revenue growth rate8.3%
Return on equity11.9%
Net Margin18.1%
Last Earnings Update31 Dec 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How CSL makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BMV:CSL N Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2211,7042,1181,9291,247
30 Sep 2211,1332,1861,7691,202
30 Jun 2210,5622,2551,6091,156
31 Mar 2210,5872,2901,6991,108
31 Dec 2110,6122,3251,7731,060
30 Sep 2110,4612,3501,7421,031
30 Jun 2110,3102,3751,7121,001
31 Mar 2110,1452,5201,612953
31 Dec 209,9802,6651,511904
30 Sep 209,5652,3841,550913
30 Jun 209,1512,1031,588922
31 Mar 209,0482,0541,557904
31 Dec 198,9442,0061,527886
30 Sep 198,7421,9621,484859
30 Jun 198,5391,9191,442832
31 Mar 198,4061,8611,441791
31 Dec 188,2741,8031,441751
30 Sep 188,0941,7661,371726
30 Jun 187,9151,7291,301702
31 Mar 187,6661,6741,251713
31 Dec 177,4171,6181,200723
30 Sep 177,1821,4781,191695
30 Jun 176,9471,3371,182667
31 Mar 176,8021,3331,118642
31 Dec 166,6561,3291,055617
30 Sep 166,3861,2861,033615
30 Jun 166,1151,2421,011614

Quality Earnings: CSL N has high quality earnings.

Growing Profit Margin: CSL N's current net profit margins (18.1%) are lower than last year (21.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CSL N's earnings have grown by 7% per year over the past 5 years.

Accelerating Growth: CSL N's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CSL N had negative earnings growth (-8.9%) over the past year, making it difficult to compare to the Biotechs industry average (-9.8%).


Return on Equity

High ROE: CSL N's Return on Equity (11.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/28 04:28
End of Day Share Price 2023/01/29 00:00
Earnings2022/12/31
Annual Earnings2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CSL Limited is covered by 28 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Saul HadassinBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Lyanne HarrisonBofA Global Research